Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylp henyl]amino]-2-pyrimidinyl] amino]benzonitrile

Details for Australian Patent Application No. 2005279158 (hide)

International Classifications

Event Publications

19 April 2007 PCT application entered the National Phase

PCT publication WO2006/024668 Priority application(s): WO2006/024668

2 August 2007 Change of Name(s) of Applicant(s), Section 104

Tibotec Pharmaceuticals Ltd.; Janssen Pharmaceutica N.V. The name of the applicant has been changed to Janssen Pharmaceutica N.V.

17 June 2010 Application Accepted

Published as AU-B-2005279158

26 August 2010 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 04 Aug 2010. Address for service in Australia - Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

16 December 2010 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 04 Aug 2010

23 December 2010 Standard Patent Sealed

12 July 2012 Extension of Term of Standard Patents

Janssen Pharmaceutica N.V. The earliest first regulatory approval date provided by the patentee 23 Dec 2011 For the goods EDURANT rilpivirine Address for service in Australia: Shelston IP Level 21 60 Margaret Street Sydney NSW 2000

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.